New scan could spot pancreatic cancer relapse months earlier
NCT ID NCT06659705
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new type of PET scan that uses a tracer called FAPI to see if it can find pancreatic cancer progression or relapse earlier than standard CT or MRI scans. 35 adults with non-spread pancreatic cancer will receive the FAPI-PET scan at several points during their treatment. The goal is to see if this imaging method can detect changes sooner, which could lead to earlier treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68Ga-FAPI-46 (a radioactive tracer used in PET scans)
What this could lead to
If successful, this imaging method could help doctors spot pancreatic cancer return or spread much earlier than current scans, potentially improving treatment timing.
What could go wrong
This is a small early-phase study (35 people) focused on imaging accuracy, not treatment. The tracer may not prove more useful than existing methods, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut Curie -site Saint-Cloud
RECRUITINGSaint-Cloud, 92210, France
Contact
Contact